MorphoSys, a company whose research has yielded programs placed with big pharmaceutical companies and upstart biotechs, is stopping all preclinical work to focus on cancer, particularly a late-stage drug candidate it acquired in a…
Continue Reading
By Sarai Rodriguez March 02, 2023 – Black women of childbearing age face a twofold risk of uncontrolled high blood pressure compared to their white counterparts, which not only fuels racial health…
Continue Reading
Scientists at the University of Massachusetts Amherst have developed a biosensor that is based on protein nanowires that are created by bacteria. The protein nanowires are highly sensitive to ammonia, in this case, which…
Continue Reading
A Fulcrum Therapeutics clinical trial testing a potential sickle cell disease drug has been paused by the FDA. With the clinical hold on the early-stage study, Fulcrum becomes the fourth company with a stalled…
Continue Reading
Moderna’s ambitions in messenger RNA technology include therapies that do their editing work inside the patient. To that end, the biotech company is starting an R&D collaboration with a division of ElevateBio that brings…
Continue Reading
Geographic atrophy, an eye disorder that starts as a loss of central vision and progressively worsens to total blindness, now has its first treatment. The FDA on Friday approved an Apellis Pharmaceuticals drug that slows the progression of this disease, which affects more than 1 million people in the U.S.
Approval of the Apellis drug, pegcetacoplan, covers all patients with geographic atrophy, a broad label that reflects the representative patient population tested in pivotal studies, Chief Medical Officer Caroline Baumal said during a Friday evening conference call. The Waltham, Massachusetts-based company plans to launch the drug in March, marketing the product under…
A Moderna messenger RNA vaccine for influenza now has preliminary data from a pivotal study showing the shot prompted a strong immune response to the more common strains of the virus but fell short against less common strains.
The results reported Thursday are from one of two pivotal studies for the Moderna vaccine, mRNA-1010, which is assessing the shot for safety and immune response. A separate Phase 3 study is evaluating the shot for efficacy. Results from that study could come as early as next month. Moderna’s vaccine encodes hemagglutinin, a protein on the surface of the influenza virus that is also…
As Reproductive Rights are Defunded and Debated Nationally, TBD Health Aims to Democratize Access to Inclusive Sexual Care
TBD Health, a sexual healthcare provider revolutionizing the medical landscape through unparalleled digital and in-person clinical care, today announced a $4.4 million seed round led by Tusk Venture Partners, with participation from Springdale Ventures, Human Ventures, Expansion VC, Starbloom Capital, Hyphen Capital, and The Community Fund along with several strategic angels. With this new financing, TBD Health is expanding to all 50 states, democratizing access to its sexual healthcare offerings, consisting of at-home STD testing and emergency contraception available via telehealth or in-person in its Las…
At a Heart Recovery Advocate Day held on February 3 at Abiomed’s Danvers, Massachusetts, headquarters, patients shared their stories of heart recovery, toured the facility, participated in lab demonstrations and had the opportunity to meet the operators who made their left ventricular assist devices, right ventricular assist devices and lung-assist devices.Connecting patients with each other, and with technologists
Beyond pictures, videos and surgical explanations, many cardiology intervention patients want to know more about the technology that enabled their heart recovery.
That is clear from the 24 survivors that experienced planned or unplanned percutaneous coronary interventions and cardiogenic shock events and who attended the largest…
It’s a new year, and healthcare technology vendors are rolling out their latest innovations, market approvals, acquisitions and staffing shake-ups.OptumRx launched Price Edge, a tool that compares pricing for traditional generic drugs to ensure members get the lowest prescription drug prices. A suite of new tools for both patients and providers target aspects of pharmacy logistics that have been known to delay or complicate care, such as getting real-time pharmacy benefits information and obtaining prior authorizations. In October, Optum, UnitedHealth Group’s pharmacy services company, merged with data clearinghouse Change Healthcare. The U.S. Department of Justice tried to block the merger and is appealing the…
Continue Reading
